Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 2
2017 2
2018 5
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.
Simioni N, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, Russo GT, Sciangula L, Lapolla A, Bette C, Rossi MC; ReaL (NN2211-4118) Study Group*. Simioni N, et al. Acta Diabetol. 2018 Jun;55(6):557-568. doi: 10.1007/s00592-018-1124-0. Epub 2018 Mar 12. Acta Diabetol. 2018. PMID: 29527621 Free PMC article.
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.
Lapolla A, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, Russo GT, Sciangula L, Simioni N, Bette C, Nicolucci A; NN2211-4118 Study Group. Lapolla A, et al. Among authors: sciangula l. Adv Ther. 2018 Feb;35(2):243-253. doi: 10.1007/s12325-017-0652-2. Epub 2017 Dec 21. Adv Ther. 2018. PMID: 29270781 Free PMC article.
Efficacy, safety and acceptability of the new pen needle 34G × 3.5 mm: a crossover randomized non-inferiority trial; AGO 02 study.
De Berardis G, Scardapane M, Lucisano G, Abbruzzese S, Bossi AC, Cipponeri E, D'Angelo P, Fontana L, Lancione R, Marelli G, Sciangula L, Nicolucci A. De Berardis G, et al. Among authors: sciangula l. Curr Med Res Opin. 2018 Sep;34(9):1699-1704. doi: 10.1080/03007995.2018.1491396. Epub 2018 Jul 5. Curr Med Res Opin. 2018. PMID: 29924641 Clinical Trial.
Efficacy of self-monitoring blood glucose as a key component of a chronic care model versus usual care in type 2 diabetes patients treated with oral agents: results of a randomized trial.
Musacchio N, Ciullo I, Scardapane M, Giancaterini A, Pessina L, Maino S, Gaiofatto R, Nicolucci A, Rossi MC; Self-Care Study Group. Musacchio N, et al. Acta Diabetol. 2018 Mar;55(3):295-299. doi: 10.1007/s00592-017-1072-0. Epub 2017 Nov 14. Acta Diabetol. 2018. PMID: 29138925 No abstract available.
Impact of the "Diabetes Interactive Diary" telemedicine system on metabolic control, risk of hypoglycemia, and quality of life: a randomized clinical trial in type 1 diabetes.
Rossi MC, Nicolucci A, Lucisano G, Pellegrini F, Di Bartolo P, Miselli V, Anichini R, Vespasiani G; Did Study Group. Rossi MC, et al. Diabetes Technol Ther. 2013 Aug;15(8):670-9. doi: 10.1089/dia.2013.0021. Epub 2013 Jul 11. Diabetes Technol Ther. 2013. PMID: 23844569 Clinical Trial.